Edition:
United Kingdom

Perrigo Company PLC (PRGO.N)

PRGO.N on New York Stock Exchange

56.99USD
14 Dec 2018
Change (% chg)

$-1.52 (-2.60%)
Prev Close
$58.51
Open
$57.93
Day's High
$58.15
Day's Low
$56.88
Volume
309,790
Avg. Vol
331,962
52-wk High
$95.82
52-wk Low
$56.88

Latest Key Developments (Source: Significant Developments)

Sol-Gel Technologies announces sixth agreement for a generic product candidate with Perrigo
Tuesday, 4 Dec 2018 

Dec 4 (Reuters) - Sol Gel Technologies Ltd ::SOL-GEL TECHNOLOGIES ANNOUNCES SIXTH AGREEMENT FOR A GENERIC PRODUCT CANDIDATE WITH PERRIGO.SOL GEL TECHNOLOGIES - ENTERED INTO SIXTH COLLABORATIVE AGREEMENT WITH PERRIGO ISRAEL FOR DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION OF GENERIC PRODUCT CANDIDATE.  Full Article

Perrigo Launches AB Rated Generic Version Of Solaraze Gel 3%
Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - Perrigo Company PLC ::PERRIGO LAUNCHES ITS AB RATED GENERIC VERSION OF SOLARAZE® GEL 3%.PERRIGO COMPANY PLC - SOLARAZE GEL, 3% IS MANUFACTURED BY PERRIGO AND SHIPPING TO CUSTOMERS HAS COMMENCED.  Full Article

Perrigo Company Says CEO Murray Kessler Reports Open Market Purchase Of 15,683 Common Shares On November 9
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Perrigo Company PLC ::PERRIGO COMPANY SAYS CEO MURRAY KESSLER REPORTS OPEN MARKET PURCHASE OF 13,416 SHARES OF COMMON STOCK AT $63.77/SHARE ON NOVEMBER 9 - SEC FILING.PERRIGO COMPANY SAYS CEO MURRAY KESSLER REPORTS OPEN MARKET PURCHASE OF 2,267 SHARES OF COMMON STOCK AT $63.89/SHARE ON NOVEMBER 9.  Full Article

Perrigo Co Q3 Loss Per Share $0.49
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Perrigo Company PLC ::REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 ADJUSTED EARNINGS PER SHARE $1.09 EXCLUDING ITEMS.Q3 GAAP LOSS PER SHARE $0.49.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $4.45 TO $4.65.SEES FY 2018 EARNINGS PER SHARE $0.66 TO $0.86.SEES FY 2018 SALES ABOUT $4.72 BILLION.Q3 SALES $1.1 BILLION.Q3 EARNINGS PER SHARE VIEW $1.01 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE VIEW $1.16 BILLION -- THOMSON REUTERS I/B/E/S.BOARD OF DIRECTORS HAS APPROVED A NEW SHARE REPURCHASE AUTHORIZATION OF UP TO $1 BILLION.PERRIGO - IN QUARTER, REALIZED IMPAIRMENT IN GOODWILL, INTANGIBLE ASSETS IN ANIMAL HEALTH REPORTING UNIT WITHIN CHC AMERICAS OF APPROXIMATELY $213 MILLION.  Full Article

Sol-Gel Technologies Ltd - Additional Collaborative Agreement With Perrigo
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Perrigo Company PLC ::SOL GEL TECHNOLOGIES LTD - ADDITIONAL COLLABORATIVE AGREEMENT FOR A GENERIC PRODUCT CANDIDATE WITH PERRIGO.SOL GEL TECHNOLOGIES LTD - PERRIGO WILL SEEK REGULATORY APPROVAL WITH FDA FOR GENERIC PRODUCT CANDIDATE.  Full Article

Perrigo Company Sets Quarterly Dividend Of $0.19 Per Share
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - Perrigo Company PLC ::SETS QUARTERLY DIVIDEND OF $0.19 PER SHARE.  Full Article

Perrigo Confirms Patent Challenge For Generic Version Of Narcan
Friday, 26 Oct 2018 

Oct 26 (Reuters) - Perrigo Company PLC ::PERRIGO CONFIRMS PATENT CHALLENGE FOR GENERIC VERSION OF NARCAN®.PERRIGO - ADAPT PHARMA OPERATIONS LTD, ADAPT PHARMA INC., ADAPT PHARMA LTD. & OPIANT PHARMACEUTICALS INITIATED PATENT LITIGATION ON OCT. 25 IN U.S. COURT.PERRIGO - PATENT LITIGATION INITIATED REGARDING CO'S PARAGRAPH IV ABBREVIATED NEW DRUG APPLICATION FOR NALOXONE HYDROCHLORIDE NASAL SPRAY 4MG.  Full Article

Emergent BioSolutions - Co's Adapt Subsidiaries And Opiant Filed Complaint
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS SAYS CO'S ADAPT SUBSIDIARIES AND OPIANT FILED COMPLAINT FOR PATENT INFRINGEMENT AGAINST PERRIGO IN U.S. COURT - SEC FILING.EMERGENT BIOSOLUTIONS - PATENT INFRINGEMENT COMPLAINT FILED ARISING FROM PERRIGO'S ANDA FILING WITH FDA FOR GENERIC VERSION OF NARCAN NASAL SPRAY 4MG/SPRAY.  Full Article

Perrigo Appoints Murray Kessler As President And CEO
Monday, 8 Oct 2018 

Oct 8 (Reuters) - Perrigo Company PLC ::PERRIGO APPOINTS MURRAY S. KESSLER AS PRESIDENT AND CHIEF EXECUTIVE OFFICER IN LINE WITH SHIFT TO CONSUMER-FOCUSED STRATEGY.PERRIGO COMPANY PLC - UWE ROEHRHOFF STEPS DOWN AS PRESIDENT, CEO.PERRIGO COMPANY PLC - ROEHRHOFF WILL REMAIN AVAILABLE TO ENSURE A SMOOTH TRANSITION.PERRIGO COMPANY PLC - KESSLER APPOINTED PRESIDENT, CEO AND MEMBER OF BOARD OF DIRECTORS EFFECTIVE IMMEDIATELY.PERRIGO COMPANY PLC - KESSLER MOST RECENTLY SERVED AS CHAIRMAN OF BOARD OF DIRECTORS AND CEO OF LORILLARD TOBACCO COMPANY.  Full Article

Perrigo Announces Final FDA Approval And Planned Launch For The Store Brand Otc Equivalent Of Imodium Multi-Symptom Relief
Friday, 7 Sep 2018 

Sept 7 (Reuters) - Perrigo Company PLC ::PERRIGO ANNOUNCES FINAL FDA APPROVAL AND PLANNED LAUNCH FOR THE STORE BRAND OTC EQUIVALENT OF IMODIUM MULTI-SYMPTOM RELIEF.PERRIGO COMPANY - FINALIZING PLANS TO LAUNCH WHOLLY OWNED STORE BRAND LOPERAMIDE HYDROCHLORIDE & SIMETHICONE TABLETS, 2 MG/125 MG, IN Q4 OF 2018.  Full Article

US STOCKS-S&P 500 edges lower ahead of Fed decision

* Wynn Resorts pulls other casino operators lower on Macau warning